AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
Patent Number: US8546091
Executive Summary:
General Description:
Currently, no biomarkers predictive of outcome in patients who received taxane-based chemotherapy have been identified. Recent meta-analyses found a significant disease-free benefit for women with breast cancer who received taxane-based therapy regardless of hormonal receptor status and HER2 status, but no biomarkers have been identified that are predictive of treatment outcome with taxanes.
Akt is a serine/threonine protein kinase (also known as protein kinase B) that has been implicated in the pathogenesis of cancer and essential cellular processes including metabolism, cell growth, proliferation, cell cycle progression, survival and differentiation. Recent preclinical studies reported that Akt-Ser473 is phosphorylated by SIN-1-rictor-mTOR complex, which is required for the cellular function such as survival and actin cytoskeletal reorganization. Importantly, paclitaxel inhibits Akt phosphorylation at serine 473 and reduces the survival cancer cells.
For the first time, investigators at NIH has found a link between the pAkt status of cancers to the efficacy of taxane treatment.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Sherry Yang
https://selectbiosciences.com/conferences/biographies.aspx?speaker=329714&conf=pmic2015
Executive Summary:
- Invention Type: Diagnostic
- Patent Status: Issued (Grant date: 2013-10-01)
- Patent Link: https://patents.google.com/patent/US8546091/
- Research Institute: National Cancer Institute
- Disease Focus: Breast cancer
- Basis of Invention: Akt is a serine/threonine protein kinase (also known as protein kinase B) that has been implicated in the pathogenesis of cancer and essential cellular processes including metabolism, cell growth, proliferation, cell cycle progression, survival and differentiation. Recent preclinical studies reported that Akt-Ser473 is phosphorylated by SIN-1-rictor-mTOR complex, which is required for cellular function and survival
- How it works: pAkt status can be used as a biomarker and indication for treatment with taxane chemotherapy. In particular, disclosed herein are methods of determining whether a subject having cancer is likely to benefit from a treatment regimen that contains treatment with a taxane compound comprising obtaining a determination of whether tissue from the subject's cancer is pAkt positive
- Lead Challenge Inventor: Sherry Yang
- Inventors: Yang; Sherry X. (Ellicott City, MD), Swain; Sandra M. (Bethesda, MD)
- Development Stage: In vivo data, validated using patient data
- Novelty: There are currently few commercially available products that can determine whether a cancer patient is likely to benefit from treatment; however, their success has been limited
- Clinical Applications: Potential method for determining whether a cancer patient is likely to benefit from treatment with a taxane compound, based on Akt-Ser473 phosphorylation status
General Description:
Currently, no biomarkers predictive of outcome in patients who received taxane-based chemotherapy have been identified. Recent meta-analyses found a significant disease-free benefit for women with breast cancer who received taxane-based therapy regardless of hormonal receptor status and HER2 status, but no biomarkers have been identified that are predictive of treatment outcome with taxanes.
Akt is a serine/threonine protein kinase (also known as protein kinase B) that has been implicated in the pathogenesis of cancer and essential cellular processes including metabolism, cell growth, proliferation, cell cycle progression, survival and differentiation. Recent preclinical studies reported that Akt-Ser473 is phosphorylated by SIN-1-rictor-mTOR complex, which is required for the cellular function such as survival and actin cytoskeletal reorganization. Importantly, paclitaxel inhibits Akt phosphorylation at serine 473 and reduces the survival cancer cells.
For the first time, investigators at NIH has found a link between the pAkt status of cancers to the efficacy of taxane treatment.
Strengths:
- Novel method
Weaknesses:
- Has not been reproduced
Patent Status:
- Priority date: 2009-05-22
- Filing date: 2010-05-21
- Publication date: 2013-10-01
- Grant date: 2013-10-01
Inventor Bio: Sherry Yang
https://selectbiosciences.com/conferences/biographies.aspx?speaker=329714&conf=pmic2015
